CYTEK BIOSCIENCES

Company Overview

Cytek Biosciences develops flow cytometry products and services. The company is the outcome of a merger between Cytek Development Inc., a flow cytometry company, and Cytoville Inc., a venture capital backed business focused on medical instrument technology development. Cytek Biosciences’ proprietary Full Spectrum Profiling (FSP) platform utilizes the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells, significantly advancing high-content cell analysis without compromising sensitivity.

From its first U.S. commercial launch in mid-2017 through December 31, 2022, Cytek Biosciences has sold and deployed more than 1,670 instruments, primarily comprised of Aurora and Northern Lights systems globally. Other than Cytek’s Northern Lights Clinical Flow Cytometry (CLC) system and certain reagents, which is available for clinical use in China and the EU, Cytek’s products are for research use only. The company’s services include onsite repair, cytometer validation and training.

Financial Highlights (FY 2024)

Company's Business Segments

• Product : Cytek Aurora Evo, Cytek Aurora, Cytek Aurora CS, Cytek Northern Lights, Cytek Orion, Cytek Amnis ImageStreamX, Cytek Muse Micro, Reagents, Others
• Services : Service Plans, Training, Validation, Design-In, Solutions, Others